Pharmadeep recently announced plans to establish a new manufacturing facility focused on producing Microcrystalline Cellulose (MCC), a widely used excipient for direct compression in pharmaceutical formulations. This marks the company’s fifth project in the active pharmaceutical ingredients (API) segment.
The project, which the company describes as a “state-of-the-art” facility, is in the initial curing stages, indicating that construction and equipment preparations are underway. The production of MCC at this new site will expand Pharmadeep’s manufacturing capacity within the API industry, adding to its diversified portfolio.
A company spokesperson highlighted that the addition of this facility reflects Pharmadeep’s ongoing involvement in API production.